荣昌生物(09995)发布公告，基于对公司未来发展的信心和对公司价值的认可，为充分激发公司员工积 极性，持续建立公司长效激励机制，并增强投资者对公司的投资信心，紧密结合公司利益、股东利益与 员工利益，综合考虑公司股价情况、经营情况、财务状况等，继续落实"提质增效重回报"行动方案，公 司拟通过集中竞价交易方式回购公司股份，回购股份将在未来合适时机用于员工持股计划或股权激励。 若公司未能在股份回购实施结果暨股份变动公告后3年内使用完毕已回购股份，尚未使用的已回购股份 将予以注销。如国家对相关政策调整，则本回购方案按调整后的政策实行。 回购股份金额为不低于人民币2000万元(含)，不超过人民币4000万元(含)。 本次回购的股份拟用于员工持股计划或股权激励，若公司未能在本次股份回购实施结果暨股份变动公告 日后 3 年内使用完毕已回购股份，尚未使用的已回购股份将予以注销。如国家对相关政策调整，则本回 购方案按调整后的政策实行。 ...

智通财经APP讯，荣昌生物(09995)发布公告，基于对公司未来发展的信心和对公司价值的认可，为充分 激发公司员工积极性，持续建立公司长效激励机制，并增强投资者对公司的投资信心，紧密结合公司利 益、股东利益与员工利益，综合考虑公司股价情况、经营情况、财务状况等，继续落实"提质增效重回 报"行动方案，公司拟通过集中竞价交易方式回购公司股份，回购股份将在未来合适时机用于员工持股 计划或股权激励。若公司未能在股份回购实施结果暨股份变动公告后3年内使用完毕已回购股份，尚未 使用的已回购股份将予以注销。如国家对相关政策调整，则本回购方案按调整后的政策实行。 回购股份金额为不低于人民币2000万元(含)，不超过人民币4000万元(含)。 本次回购的股份拟用于员工持股计划或股权激励，若公司未能在本次股份回购实施结果暨股份变动公告 日后 3 年内使用完毕已回购股份，尚未使用的已回购股份将予以注销。如国家对相关政策调整，则本回 购方案按调整后的政策实行。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 榮昌生物製藥（煙台）股份有限公司 董事長兼執行董事 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由榮昌生物製藥 （煙台）股份有限公司（「本公司」）作出。 茲載列本公司於上海證券交易所網站刊登公告如下，僅供參閱。 承董事會命 王威東先生 中國煙台 2025年12月15日 於本公告日期，董事會成員包括執行董事王威東先生、房健民博士、林健先生及 溫慶凱先生；非執行董事王荔強博士及蘇曉迪博士；及獨立非執行董事郝先經先 生、陳雲金先生及黃國濱先生。 * 僅供識別 证券代码：688331 证券简称：荣昌生物 公告编号：2025-055 荣昌生物制药（烟台）股份有限公司 关于以集中竞价交易方式回购股份的预案 本公司董事会及全体董 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 王威東先生 中國煙台 2025年12月15日 於本公告日期，董事會成員包括執行董事王威東先生、房健民博士、林健先生及 溫慶凱先生；非執行董事王荔強博士及蘇曉迪博士；及獨立非執行董事郝先經先 生、陳雲金先生及黃國濱先生。 * 僅供識別 证券代码：688331 证券简称：荣昌生物 公告编号：2025-054 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由榮昌生物製藥 （煙台）股份有限公司（「本公司」）作出。 茲載列本公司於上海證券交易所網站刊登公告如下，僅供參閱。 承董事會命 榮昌生物製藥（煙台）股份有限公司 董事長兼執行董事 港股代码：09995 港股简称：榮昌生物 荣昌生物制药（烟台）股份有限公司 第二届董事会第三 ...

Core Viewpoint - On December 15, several A-share listed companies disclosed their share repurchase and reduction plans, indicating varying levels of confidence among management and shareholders in their respective companies [1][4]. Summary of Buyback Situations - Rongchang Bio plans to repurchase shares worth between 20 million to 40 million yuan [5]. - Digital Video intends to buy back shares valued at 80 million to 120 million yuan [5]. - AVIC Heavy Machinery's directors and senior management plan to increase their holdings in the company [5]. Summary of Reduction Situations - Baoming Technology's directors and supervisors plan to reduce their holdings by no more than 0.0469% [6]. - Shifeng Culture's shareholder Cai Junquan and his concerted parties intend to reduce their holdings by no more than 3% [6]. - Shengong Co., Ltd. shareholders Wenzhou Jingli and Xujie Investment plan to reduce their holdings by no more than 1.98% [6]. - Demai Chemical's shareholder Chang Lianrong plans to reduce by no more than 3% [6]. - Hualong Aluminum's shareholder You Xiaohua plans to reduce by no more than 2.17% [6]. - Zhangjiang Hi-Tech's controlling shareholder has completed a reduction of 1% of the company's shares [6]. - Jixiang Airlines' shareholder Dongfang Chuantou plans to reduce by no more than 1% [6]. - Decai Co., Ltd.'s shareholder Cheng Gao Century plans to reduce by no more than 3% [6]. - Fujian Cement reduced its holdings by 280,200 shares on December 15 [6]. - Kehua Holdings' shareholder Zhang Yu plans to reduce by no more than 3% [6]. - Western Gold's shareholder Yang Shengrong reduced his holdings by 14.0725 million shares from November 10 to December 15 [6].

（文章来源：证券日报） 证券日报网讯 12月15日晚间，荣昌生物发布公告称，公司第二届董事会第三十二次会议审议通过《关 于以集中竞价交易方式回购公司股份方案的议案》等多项议案。 ...

Group 1 - Muxi Co., Ltd. will list its common stock on the Sci-Tech Innovation Board on December 17, 2025 [1] - Xinghua New Materials signed a strategic cooperation agreement with Guoteng Company to collaborate in the quantum technology field [2] - TCL Technology's subsidiary plans to acquire a 10.7656% stake in Shenzhen Huaxing Semiconductor for 60.45 billion RMB [3] Group 2 - Jingjia Micro's subsidiary has completed key stages of its edge AI SoC chip, marking a significant project breakthrough [4] - Cambricon plans to use 2.778 billion RMB of its capital reserve to offset losses [5] - Bojun Technology's subsidiary intends to invest 600 million RMB in an automotive lightweight component production base in Chongqing [6] Group 3 - Longqi Technology plans to invest approximately 1.5 billion RMB to build an AI + smart terminal digital benchmark factory in Nanchang [7] - Taili Technology signed a strategic cooperation framework agreement with Jinan University to establish an advanced functional materials research institute with an investment of 100 million RMB [8][9] - Pengding Holdings plans to invest a total of 4.297 billion RMB in a production facility in Thailand by 2026 [10] Group 4 - China Metallurgical Group reported a new contract amount of 958.13 billion RMB from January to November 2025, a decrease of 8.6% year-on-year [16] - 吉祥航空 reported an 8.92% year-on-year increase in passenger turnover in November 2025 [17] - Hainan Airport's passenger throughput reached 2.0909 million in November 2025, a year-on-year increase of 8.16% [20] Group 5 - Xinhua Insurance reported a cumulative original insurance premium income of 188.85 billion RMB from January to November 2025, a year-on-year increase of 16% [21] - Huafeng Aluminum's controlling shareholder plans to reduce its stake by up to 2.17% [22] - Digital Vision plans to repurchase shares worth 80 million to 120 million RMB [23]

荣昌生物表示，回购股份的目的是基于对公司未来发展的信心和对公司价值的认可，为充分激发公司员 工积极性，持续建立公司长效激励机制，并增强投资者对公司的投资信心，紧密结合公司利益、股东利 益与员工利益，综合考虑公司股价情况、经营情况、财务状况等，继续落实"提质增效重回报"行动方 案。 北京商报讯（记者 丁宁）12月15日晚间，荣昌生物（688331）发布公告称，公司拟通过集中竞价交易 方式回购公司A股股份，回购股份金额不低于2000万元（含），不超过4000万元（含），回购股份将在 未来合适时机用于员工持股计划或股权激励。 ...

（编辑 任世碧） 证券日报网讯 12月15日晚间，荣昌生物发布公告称，公司拟以集中竞价交易方式回购股份，回购股份 将用于员工持股计划或股权激励，回购金额不低于2000万元且不超过4000万元，资金来源为自有资金 和/或自筹资金，回购价格不超过95元/股。回购股份期限：自公司董事会审议通过本次股份回购方案之 日起12个月内。 ...

Group 1 - Shareholder Zhang Yu of Kehua Holdings plans to reduce his stake by up to 3%, amounting to no more than 5.83 million shares within three months [1] - Shanghai Ailu has signed a strategic cooperation agreement with Southern Road Machinery to provide packaging products for the dry-mixed mortar industry [2] - Xingyuan Zhuomei appointed Gong Chunming as the new deputy general manager [3] Group 2 - Tongyi Zhong's shareholder has set a preliminary transfer price of 15.47 yuan per share for a total of 4.27 million shares [4] - Anada's shareholder did not implement the planned share reduction of up to 2% by the deadline [5] - Rongchang Bio plans to repurchase shares worth between 20 million to 40 million yuan at a price not exceeding 95 yuan per share [6] Group 3 - Hainan Airport reported an 8.16% year-on-year increase in passenger throughput for November, totaling 2.09 million passengers [7] - Lanjian Intelligent plans to apply for a bank credit line of up to 1.2 billion yuan for various financial operations [8] - Xinlei Co. received a total of 561.43 million yuan in land acquisition and compensation payments [9] Group 4 - Foster reported a surplus of 321 million yuan from four fundraising projects, which will be used to supplement working capital [10] - China Southern Airlines experienced a 10.42% year-on-year increase in passenger turnover for November [12] - China National Airlines reported a 10.1% year-on-year increase in passenger turnover for November [17] Group 5 - Sanyou Chemical plans to register and issue mid-term notes not exceeding 1.3 billion yuan [18] - Quanyuan Spring used 60 million yuan of idle funds to purchase structured deposits [19] - Su Keng Agricultural Development appointed Zou Yi as the new deputy general manager [20] Group 6 - Jingneng Real Estate received approval to register mid-term notes totaling up to 2 billion yuan [21] - Dechang Co. received approval from the CSRC for a targeted issuance of shares [23] - Jiufeng Bio obtained a medical device registration certificate for its fructosamine testing kit [24] Group 7 - Jinzi Ham's president Guo Bo resigned for personal reasons, while Zheng Hu was appointed as the new president [25] - China Eastern Airlines reported a 10.35% year-on-year increase in passenger turnover for November [26] - Fengfan Co.'s controlling shareholder is in the process of acquiring 17.32% of the company's shares [27] Group 8 - Zhenghai Bio signed a technical development contract with the Chinese Academy of Agricultural Sciences for a collagen product project worth 12 million yuan [28] - Xinhua Insurance reported a 16% year-on-year increase in cumulative original insurance premium income for the first 11 months [29] - Jingjia Microelectronics' subsidiary completed key stages of its AI SoC chip project [30] Group 9 - Shanghai Pharmaceuticals' hydrochloride sotalol tablets passed the consistency evaluation for generic drugs [31] - Heshun Technology's subsidiary's carbon fiber project has entered a stable operational phase [32] - Spring Airlines reported an 18.02% year-on-year increase in passenger turnover for November [33] Group 10 - Huaxin New Materials proposed a mid-term dividend plan of 1 yuan per 10 shares [34] - Keda Li plans to increase capital by 300 million yuan for its wholly-owned subsidiary [35] - Jinguang Electric won a bid for a high-voltage direct current transmission project worth 84.86 million yuan [36] Group 11 - XGIMI Technology's subsidiary received a development notification for a vehicle-mounted projection project from a well-known domestic automotive manufacturer [37]